Novartis AG Receivables 2010-2024 | NVS
Novartis AG receivables from 2010 to 2024. Receivables can be defined as the total amount of collectibles for a company
- Novartis AG receivables for the quarter ending September 30, 2024 were $8.150B, a 14.8% increase year-over-year.
- Novartis AG receivables for 2023 were $7.533B, a 9.61% decline from 2022.
- Novartis AG receivables for 2022 were $8.334B, a 0.62% increase from 2021.
- Novartis AG receivables for 2021 were $8.283B, a 2.05% decline from 2020.
Novartis AG Annual Receivables
(Millions of US $) |
| 2023 |
$7,533 |
| 2022 |
$8,334 |
| 2021 |
$8,283 |
| 2020 |
$8,456 |
| 2019 |
$8,555 |
| 2018 |
$8,975 |
| 2017 |
$8,802 |
| 2016 |
$8,358 |
| 2015 |
$8,180 |
| 2014 |
$8,275 |
| 2013 |
$9,902 |
| 2012 |
$10,051 |
| 2011 |
$10,323 |
| 2010 |
$9,873 |
| 2009 |
$8,310 |
Novartis AG Quarterly Receivables
(Millions of US $) |
| 2024-09-30 |
$8,150 |
| 2024-06-30 |
$8,480 |
| 2024-03-31 |
$8,251 |
| 2023-12-31 |
$7,533 |
| 2023-09-30 |
$7,099 |
| 2023-06-30 |
$9,543 |
| 2023-03-31 |
$9,183 |
| 2022-12-31 |
$8,334 |
| 2022-09-30 |
$8,680 |
| 2022-06-30 |
$8,910 |
| 2022-03-31 |
$8,678 |
| 2021-12-31 |
$8,283 |
| 2021-09-30 |
$8,632 |
| 2021-06-30 |
$8,654 |
| 2021-03-31 |
$8,481 |
| 2020-12-31 |
$8,456 |
| 2020-09-30 |
$8,299 |
| 2020-06-30 |
$7,952 |
| 2020-03-31 |
$8,795 |
| 2019-12-31 |
$8,555 |
| 2019-09-30 |
$8,070 |
| 2019-06-30 |
$8,252 |
| 2019-03-31 |
$7,845 |
| 2018-12-31 |
$8,975 |
| 2018-09-30 |
$8,766 |
| 2018-06-30 |
$8,989 |
| 2018-03-31 |
$9,116 |
| 2017-12-31 |
$8,802 |
| 2017-09-30 |
$8,482 |
| 2017-06-30 |
$8,380 |
| 2017-03-31 |
$8,234 |
| 2016-12-31 |
$8,358 |
| 2016-09-30 |
$8,547 |
| 2016-06-30 |
$8,606 |
| 2016-03-31 |
$8,464 |
| 2015-12-31 |
$8,180 |
| 2015-09-30 |
$8,495 |
| 2015-06-30 |
$8,750 |
| 2015-03-31 |
$8,794 |
| 2014-12-31 |
$8,275 |
| 2014-09-30 |
$8,857 |
| 2014-06-30 |
$9,371 |
| 2014-03-31 |
$10,324 |
| 2013-12-31 |
$9,902 |
| 2013-09-30 |
$10,502 |
| 2013-06-30 |
$10,792 |
| 2013-03-31 |
$10,484 |
| 2012-12-31 |
$10,051 |
| 2012-09-30 |
$10,519 |
| 2012-06-30 |
$10,487 |
| 2012-03-31 |
$10,605 |
| 2011-12-31 |
$10,323 |
| 2011-09-30 |
$10,703 |
| 2011-06-30 |
$10,915 |
| 2011-03-31 |
$10,861 |
| 2010-12-31 |
$9,873 |
| 2010-09-30 |
$10,391 |
| 2010-06-30 |
$7,798 |
| 2010-03-31 |
$7,773 |
| 2009-12-31 |
$8,310 |
| 2009-09-30 |
$7,817 |
| 2009-06-30 |
$7,167 |
| 2009-03-31 |
$6,751 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$217.584B |
$45.440B |
|
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
|
